Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.280
-0.070 (-1.61%)
Dec 5, 2025, 4:00 PM EST - Market closed
Voyager Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Voyager Therapeutics stock have an average target of 16.17, with a low estimate of 8.00 and a high estimate of 30. The average target predicts an increase of 277.80% from the current stock price of 4.28.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Voyager Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 5 | 5 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $25 | Strong Buy | Maintains | $30 → $25 | +484.11% | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +600.93% | Sep 15, 2025 |
| Wedbush | Wedbush | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +86.92% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +600.93% | Apr 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $12 | Strong Buy | Maintains | $14 → $12 | +180.37% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
36.24M
from 80.00M
Decreased by -54.70%
Revenue Next Year
62.25M
from 36.24M
Increased by 71.78%
EPS This Year
-2.13
from -1.13
EPS Next Year
-1.63
from -2.13
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 51.5M | 148.0M | ||||
| Avg | 36.2M | 62.3M | ||||
| Low | 27.5M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -35.6% | 308.4% | ||||
| Avg | -54.7% | 71.8% | ||||
| Low | -65.7% | -89.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.01 | -0.67 | ||||
| Avg | -2.13 | -1.63 | ||||
| Low | -2.24 | -2.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.